Bionano Genomics Q2 2024 GAAP EPS $(0.24) Beats $(0.42) Estimate, Sales $7.771M Miss $8.003M Estimate
Portfolio Pulse from Benzinga Newsdesk
Bionano Genomics (NASDAQ:BNGO) reported Q2 2024 GAAP EPS of $(0.24), beating the $(0.42) estimate, but sales of $7.771M missed the $8.003M estimate. EPS improved by 80.65% YoY, while sales decreased by 10.29% YoY.
August 07, 2024 | 11:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bionano Genomics reported Q2 2024 GAAP EPS of $(0.24), beating the $(0.42) estimate, but sales of $7.771M missed the $8.003M estimate. EPS improved by 80.65% YoY, while sales decreased by 10.29% YoY.
The significant improvement in EPS, beating estimates by a large margin, is a positive indicator for the stock. However, the miss on sales and the YoY decline in revenue may temper the positive impact. Overall, the market is likely to react positively in the short term due to the strong EPS performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100